Eric Chen, Ph.D.


Eric is the vice president of commercial at Origin Biosciences. In this role, he leads the company’s commercial preparation for the potential launch of its compound in development for the treatment of Molybdenum Cofactor Deficiency (MoCD) Type A. He has spent most of his career focused on the development and commercialization of novel therapeutics, primarily in rare diseases and oncology. Prior to Origin, Eric was at Horizon Pharma where he was product core team leader for teprotumumab and senior director of commercial development for the orphan business unit, responsible for pipeline programs, lifecycle management, and business development. Eric joined Horizon through the acquisition of Raptor Pharmaceuticals where he was head of global marketing, strategy and analytics. He has also held roles of increasing responsibility in commercial and business development at Onyx Pharmaceuticals, Halozyme Therapeutics, and Biogen Idec. He began his career as a consultant at Cap Gemini Ernst & Young. Eric earned his Ph.D. in management science & engineering from Stanford University and B.S. in economics from MIT.